People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Kazia Therapeutics Ltd | — | Biotechnology | Series C | $61.4M | $286.5M | 2025 |
Elissa Hansen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elissa Hansen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John Friend | 1 | 3 |
| Steven Coffey | 1 | 2 |
| Robert Apple | 1 | 2 |
| Karen Krumeich | 1 | 1 |
| Bryce Carmine | 1 | 1 |
| Ebru Davidson | 1 | 1 |
| Jeffrey Bonacorda | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.